Skip to main content

Table 3 Cox regression analysis of the progression-free survival

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

  Univariate Multivariate
Variables HR (95% C.I.) p-value HR (95% C.I.) p-value
Age 0.99 (0.96–1.01) 0.344
Sex (male) 1.04 (0.53–2.04) 0.751
Smoking history 0.79 (0.28–2.23) 0.608  
ECOG PS 0–1 0.10 (0.03–0.29) < 0.001 0.09 (0.02–0.33) < 0.001
Brain metastasis 1.61 (0.82–3.17) 0.119 1.22 (0.58–2.56) 0.594
Cause of crizotinib treatment failure: Resistancea 2.64 (1.26–5.51) 0.009 2.75 (1.26–5.99) 0.011
Prior chemotherapy 1.18 (0.61–2.27) 0.630
Alectinib vs. ceritinib 0.61 (0.31–1.13) 0.135 0.68 (0.33–1.37) 0.277
  1. ECOG PS Eastern Cooperative Oncology Group performance status; a as opposed to crizotinib intolerance